AURINIA PHARMACEUTICALS Stock (AUPH.re) Price Chart, Analysis, and Forecast

View the real-time AURINIA PHARMACEUTICALS (AUPH.re) stock quote and decide if you want to buy and when to sell. Find predictions, financials, the latest news and other information to help you with your stock investing.

买入
卖出
日价格变动区间：
交易 [object Object]

All investing involves risk

live price

Live Chart

Past performance is not a reliable indicator of future results.

Is AURINIA PHARMACEUTICALS a good stock to buy?

The quantitative stock rating system created by TipRanks shows that AURINIA PHARMACEUTICALS price is overperforming. Its Smart Score¹ of 9 indicates AURINIA PHARMACEUTICALS is one of the best stocks to buy or watch now in May.

9

Smart Score

Why is AURINIA PHARMACEUTICALS stock price going up?

AURINIA PHARMACEUTICALS

Bulls say

  • Acquisition terms

    Acquisition brings a novel autoimmune drug into the portfolio at a near-net minimal cash outlay because the target had a strong cash balance and includes contingent value payments that align future payouts with development and cash milestones.

  • Clinical pipeline signals

    Proof-of-concept efficacy for the acquired autoimmune asset and strong early clinical reductions in immunoglobulins for the aritinercept program support meaningful pipeline upside if safety and registrational strategies are clarified, with once-monthly dosing potentially enhancing competitive positioning.

  • Guideline-driven commercial momentum

    Lupkynis sales are strengthening as updated lupus nephritis and rheumatology guidelines encourage proactive proteinuria screening and favor calcineurin inhibitors, increasing new patient starts, hospital use, and treatment persistence.

Why is AURINIA PHARMACEUTICALS stock price going down?

AURINIA PHARMACEUTICALS

Bears say

  • Intellectual property risk

    Multiple generic challenges to the company's key dosing patent and ongoing patent litigation threaten long-term exclusivity, risking reduced future sales and increased legal and defense costs.

  • Regulatory uncertainty

    Unresolved alignment with regulators on registrational trial design and a cancelled regulatory meeting introduce uncertainty around the approval pathway, potentially forcing strategic changes and cost-conserving measures.

  • Safety concerns

    Fatal events reported in a clinical trial raise serious safety concerns that create material clinical and regulatory risk and could delay or halt development for the affected program.

What is happening with
AURINIA PHARMACEUTICALS stock price today?

  • The price of AURINIA PHARMACEUTICALS today, as of , was $. That's down % from the previous session's AURINIA PHARMACEUTICALS closing price.

  • The AURINIA PHARMACEUTICALS price is declining this week. Compared to last week, the rate of AURINIA PHARMACEUTICALS is down --, and it's down -- from one month ago.

  • The 52-week AURINIA PHARMACEUTICALS price high is $, while the 52-week AURINIA PHARMACEUTICALS price low is $.

  • Year to date, AURINIA PHARMACEUTICALS price is down -- from the beginning of the year and has had a return of -- in the last 12 months.

What is the sentiment of AURINIA PHARMACEUTICALS stock in May 2026?

The sentiment score², indicating how the crowd feels about AURINIA PHARMACEUTICALS stock is POSITIVE. The sentiment signal³ observed at the start of the market session, offering insights into whether AURINIA PHARMACEUTICALS stock price today is likely to increase, decrease, or remain steady, is BULLISH.

News Sentiment
Very Bullish
Very Bullish
Bullish: 100%Bearish: 0%
Blogger Opinion
Bullish
Bullish
Bullish: 100%Bearish: 0%
Investors Sentiment
Very Negative
Very Negative
Past 7d: -1%Past 30d: -1%

Table with the sentiment of AURINIA PHARMACEUTICALS stock in May 2026

AURINIA PHARMACEUTICALS stock analysis

Based on analysts giving ratings to AURINIA PHARMACEUTICALS stock, the consensus⁴ is BUY. Hedge funds activity⁵ N/A in the last quarter, while Insider activity⁶ trend is N/A (N/A AURINIA PHARMACEUTICALS shares)

AURINIA PHARMACEUTICALS Technical Analysis

Trending upPositive
SMA
Trending up0.87
Momentum

Simple moving average: 20/200 days

Momentum: 12 month change

AURINIA PHARMACEUTICALS Insider Activity

No data available

AURINIA PHARMACEUTICALS Fundamentals

Trending up+64.0%
Return on equity
Trending up+40.0%
Asset Growth

Return on equity: last 12 months

Asset growth: 12 month change

Discover key AURINIA PHARMACEUTICALS stock trends with NAGA Insights

What am I Missing?

  • Make informed decisions based on real-time data, expert analysis, and powerful research tools from TipRanks.

  • Access advanced AURINIA PHARMACEUTICALS charting, technical analysis, and live market data from TradingView.

  • Get AI-powered AURINIA PHARMACEUTICALS trade signals, in-depth market analysis, and technical strategy insights from Trading Central.

Sign up

All investing involves risk

Best Stocks Discover

AURINIA PHARMACEUTICALS stock outlook 2026

Analysts forecast AURINIA PHARMACEUTICALS stock price will rise/fall in the next 12 months. Based on 4 Wall Street analysts offering AURINIA PHARMACEUTICALS price predictions in the last 3 months, the average price target is $16.00.

The highest AURINIA PHARMACEUTICALS stock forecast is $17.00, while the lowest is $15.00. The average AURINIA PHARMACEUTICALS price target represents a 5.06% change from the actual price of $.

AURINIA PHARMACEUTICALS stock price prediction⁷

  • Highest price target$17.00
  • Average price target$16.00
  • Lowest price target$15.00

AURINIA PHARMACEUTICALS stock forecast⁸

  • Buy50.00%
  • Hold50.00%
  • Sell0.00%

Overview of stock forecast and price predictions 2026. Analyst price targets and consensus are estimates only and do not constitute guarantees of future outcomes.

Investing in AURINIA PHARMACEUTICALS stock

There are two ways to invest in AURINIA PHARMACEUTICALS stock: trading AURINIA PHARMACEUTICALS stock through derivatives like CFDs or buying shares of AURINIA PHARMACEUTICALS stock outright. With NAGA.com, you can do both and more.


Buy AURINIA PHARMACEUTICALS shares of stock if you want to hold them for a long time. You commit the full value of the AURINIA PHARMACEUTICALS shares outright and profit only if they increase in price.


Trade AURINIA PHARMACEUTICALS if you want more flexibility — say you want to speculate on its price movements in both directions. With CFDs, you can open a buy position (go long) if you think AURINIA PHARMACEUTICALS stock’s price will rise, or you can open a sell position (go short) if you believe the AURINIA PHARMACEUTICALS stock’s price will fall.


You won’t need to commit to the full value of the position. But bear in mind that leverage can increase both your profits and losses.

How to invest

How to trade AURINIA PHARMACEUTICALS with CFDs?

  • If you want to speculate on AURINIA PHARMACEUTICALS price, search for AURINIA PHARMACEUTICALS CFD. Then click on the "AURINIA PHARMACEUTICALS" symbol to view the chart and other insights before placing your trade. Also, review "AURINIA PHARMACEUTICALS" contract specification to be aware of all the AURINIA PHARMACEUTICALS CFD trading conditions.

How to buy AURINIA PHARMACEUTICALS stock?

  • If you want to buy AURINIA PHARMACEUTICALS shares outright to hold them for a long time, search for AURINIA PHARMACEUTICALS stock with ownership (Real Stocks). Then click on the "AURINIA PHARMACEUTICALS" symbol to view the chart and other insights before placing your trade. Also, review "AURINIA PHARMACEUTICALS" contract specification to be aware of all the AURINIA PHARMACEUTICALS stock buying conditions.

trading conditions:

平台
MT5
交易单
交易量阶梯
手数值
最小交易规模
最大交易规模
佣金
月度价格变化(%)0.00%
年度价格变化(%)0.00%
数
最小价格变动值
交易时段及费用
Get Started

All investing involves risk

AURINIA PHARMACEUTICALS company presentation

AUPH

Aurinia Pharmaceuticals

Real Stocks

--
--

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Latest AURINIA PHARMACEUTICALS stock news

Discover the latest news that can influence AURINIA PHARMACEUTICALS’s earnings sentiment and AURINIA PHARMACEUTICALS forecast and price predictions.

Positive
RBC Capital Sticks to Their Hold Rating for Aurinia Pharmaceuticals (AUPH)
08/05/2026/09:02
Read more
Positive
TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
07/05/2026/12:46
Read more
Positive
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
07/05/2026/09:32
Read more

FAQs about AURINIA PHARMACEUTICALS trading

The price of AURINIA PHARMACEUTICALS stock today, as of , was . That's down % from the previous session's AURINIA PHARMACEUTICALS closing price.

IMPORTANT NOTICE: The content presented in the instrument page is only for informational, educational and support purposes. The material presented, including analyses, sentiment, consensus, prices, opinions or other content, is not an investment recommendation or information that recommends or suggests an investment strategy, nor is it included in the scope of investment advice. NAGA will not accept liability for any loss or damage, including but not limited to any loss of profits, that may arise directly or indirectly from the use of or reliance on the information contained in this page. NAGA is not responsible for the actions or omissions of the client, especially for the acquisition or disposal of financial instruments, made based on the information contained in this page. Past performance is not necessarily indicative of future results, and anyone acting on this information does so at their own risk. ¹ ⁵ ⁶ The Smart Score is a proprietary quantitative stock scoring system created by TipRanks. It assigns stocks a score from one to ten, based on 8 market key factors. The lowest score is 1, and the highest is 10. Stocks with a score of 8, 9, or 10 are considered Outperform, and with a score of 1, 2, or 3 are considered Underperform. The score is data-driven and does not involve any human intervention. The contributing market factors are Wall Street analyst ratings, Corporate insider transactions, Financial blogger opinions, Individual investor sentiment, Hedge fund manager activity, News sentiment, Technicals and Fundamentals. This information is provided for indicative purposes only and should not be interpreted as investment advice or a recommendation to trade. ⁴ ⁷ ⁸ TipRanks’ consensus ratings provide an aggregated view of expectations and consensus on a particular stock from a wide range of global analyst opinions. They’re then condensed into a single indicator, which can help you make investment decisions based on expert analysis. TipRanks’ 12-month forecast is a consensus price target derived from Wall Street analysts’ projections made over the past three months. It forecasts the potential high, low, and average share price for a stock one year from now, along with the average expected upside or downside percentage. ² ³ The sentiment signal and sentiment score are provided by Trading Central. Sentiment insights and market views are based on available data and do not guarantee future performance.

需要帮忙？前往我们的帮助部分
Download NAGA Trader

版权 © 2026 – 保留所有权利。

NAGA是德国金融科技公司The NAGA Group AG的商标，该公司在法兰克福证券交易所公开上市 | WKN: A41YCM | ISIN: DE000A41YCM0。

该网站由NAGA Capital Ltd运营，该公司获得塞舌尔金融服务管理局（FSA）授权和监管，许可证号为SD026。注册地址为 Suite 3, Jivan’s Complex, Global Village, Mont Fleuri, Mahe, Seychelles。 Tel: +248 4373121

其他集团实体：NAGA Markets Europe Ltd，获得塞浦路斯证券交易委员会（"CySEC"）授权和监管，许可证号为204/13，注册地址为Agias Zonis 11, Limassol, 3027, Cyprus，以及NAGA Global (CY) Ltd，注册地址为Nikokreontos 2, NICE DREAM, 6th floor, Flat/Office 601, 1066, Nicosia, Cyprus。

风险警告： 衍生品是复杂的工具，由于杠杆作用，存在快速亏损的高风险。您应考虑是否了解衍生品的运作方式以及是否能够承担亏损的高风险。这不是投资建议。通过NAGA Trader跟随和/或复制或复制其他交易者的交易涉及高风险，即使是跟随和/或复制或复制主要交易者的交易。这些风险包括您可能跟随/复制可能没有经验/不专业的交易者的交易决策，或其最终目的或意图或财务状况可能与您不同的交易者。在做出投资决策之前，您应依靠自己对做出交易决策的人的评估以及所有法律文件条款的评估。

受限国家： NAGA Capital Ltd不为某些国家的居民提供服务，例如阿富汗、阿尔巴尼亚、美属萨摩亚、安圭拉、澳大利亚、奥地利、巴巴多斯、白俄罗斯、比利时、百慕大、英属印度洋领地、保加利亚、布基纳法索、加拿大、开曼群岛、中非共和国、圣诞岛、科科斯（基林）群岛、刚果民主共和国、克罗地亚、塞浦路斯、捷克共和国、丹麦、爱沙尼亚、福克兰群岛（马尔维纳斯）、芬兰、法国、德国、直布罗陀、希腊、关岛、海地、赫德岛和麦克唐纳群岛、匈牙利、冰岛、伊朗伊斯兰共和国、爱尔兰、马恩岛、以色列、意大利、牙买加、日本、泽西岛、朝鲜民主主义人民共和国、拉脱维亚、利比亚阿拉伯民众国、列支敦士登、立陶宛、卢森堡、马里、马耳他、蒙特塞拉特、莫桑比克、缅甸、荷兰、新西兰、诺福克岛、挪威、巴勒斯坦被占领土、皮特凯恩、波兰、葡萄牙、罗马尼亚、圣赫勒拿、阿森松和特里斯坦达库尼亚、圣马力诺、塞内加尔、塞尔维亚、斯洛伐克、斯洛文尼亚、索马里、南乔治亚和南桑威奇群岛、南苏丹、西班牙、斯里兰卡、瑞典、瑞士、阿拉伯叙利亚共和国、特立尼达和多巴哥、突尼斯、特克斯和凯科斯群岛、乌干达、英国及任何其他拥有英国身份证明的国家（即英属维尔京群岛、直布罗陀、马恩岛等）、美国、美国小离岛、瓦努阿图、英属维尔京群岛、美属维尔京群岛、也门和津巴布韦。